Pfizer Inc. $PFE Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its position in Pfizer Inc. (NYSE:PFE) by 7.2% during the third quarter, HoldingsChannel.com reports. The fund owned 3,309,180 shares of the biopharmaceutical company’s stock after acquiring an additional 223,460 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Pfizer were worth $86,923,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the second quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the second quarter valued at $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 1.0%

NYSE PFE traded down $0.26 during trading on Tuesday, reaching $25.39. 10,015,089 shares of the company’s stock were exchanged, compared to its average volume of 45,020,793. The company’s fifty day simple moving average is $25.38 and its 200-day simple moving average is $24.99. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $144.38 billion, a PE ratio of 14.78 and a beta of 0.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer secured a license to use Novavax’s Matrix‑M adjuvant for vaccine development, which could accelerate and broaden Pfizer’s infectious‑disease vaccine programs and reduce development risk/costs — a clear pipeline positive. Novavax enters license agreement with Pfizer for vaccine development Novavax stock rises after licensing Matrix-M adjuvant to Pfizer
• Neutral Sentiment: Analysts and investors are reassessing Pfizer’s valuation and recent shareholder‑return programs; this discussion can create short‑term volatility as the market re‑prices future cash flows versus buybacks/dividends. Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns
• Neutral Sentiment: Q4/near‑term expectations center on continued Eliquis growth offset by softer COVID‑19 sales and steady demand for other non‑oncology drugs; upcoming results/guidance will matter for near‑term sentiment. What to Expect From Pfizer’s Non-Oncology Business in Q4?
• Neutral Sentiment: Thematic ETF coverage of weight‑loss/GLP‑1 exposure mentions Pfizer in broader healthcare context; that’s background noise unless Pfizer announces a direct GLP‑1 play. Ozempic, Mounjaro, Wegovy, or Zepound? This ETF Holds Them All (PFE)
• Negative Sentiment: Pfizer is restructuring its holdings in the ViiV HIV joint venture (Pfizer exiting; Shionogi increasing stake), which reduces Pfizer’s future exposure to a durable HIV revenue stream — potential long‑term revenue headwind. Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
• Negative Sentiment: Commentary noting Pfizer’s multi‑year share decline (consumer pieces on “down 55%”) highlights investor worry about patent cliffs and recent drug setbacks; that narrative can add selling pressure absent fresh positive data or clearer guidance. Down 55%, Should You Buy the Dip on Pfizer?

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Morgan Stanley decreased their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. HSBC restated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.